The whole advantage of T3 therapy is that patients’ symptoms often remain improved even after they have discontinued T3 therapy. Sometimes the symptoms do not remain improved after the treatment has been discontinued (Q16), but it is extremely unlikely that any patient’s symptoms will be persistently worse after T3 therapy than they were prior to T3 therapy.